Personal profile
Personal profile
Previously to be an independent investigator Dr. Irarrázabal participate in several investigations in the Universidad de Chile. One of his most interesting research was to clarify the mechanisms involved in the specificity of the amino acid transporter y+L system in the human erythrocyte. Besides, he participates in an initiative from the Organization of American States to disseminate the biotechnology interaction between academics and industry. He was co-editor of two books in this area. During his doctoral thesis, he was awarded with two government support grants. The doctoral thesis help to identifies a p53 gene polymorphisms in humans associated with lung cancer susceptibility. After finished the Ph.D. program in the Universidad de Chile, he moved to Bethesda City in the U.S.A. to carry out his postdoc training in renal physiology in the National Institutes of Health (NIH-USA) under the supervision of Dr. Maurice Burg. In NIH, his contribution provided important evidence to understand how the cells survived in hypertonic condition in kidney, helping to clarify the knowledge of the renal function and the osmotic stress response signaling pathway. Right now, he is a full professor and Chief of the Laboratory of Integrative and Molecular Physiology in the Universidad de los Andes (UANDES) in Chile. He has over 30 publications that have been cited over 500 times, and his publication H-index is 18 and has been serving as an editorial board member of reputed Journals. In the UANDES, he has worked in more than 10 research projects generating two patents for clinical application in hypoxia and renal damage.
Education/Academic qualification
PhD, Ciencias Biomédicas, Universidad de Chile
… → 2001
University Degree, Bioquímico, Universidad de Chile
External positions
Fellow Post-Doc, The National Institutes of Health
25 Jun 2002 → 25 Jun 2007
Research Lines
- Research Lines
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 10 Finished
-
FONDECYT POSTDOCTORADO - 3230322: LA EXPRESIÓN DE HSP70 EN LA MEMBRANA DE VESÍCULAS EXTRACELULARES PREVIENEN EL DAÑO RENAL INDUCIDO POR ISQUEMIA/REPERFUSIÓN EN RATÓN.
Irarrazabal Muñoz, C. E. (Sponsoring Researcher) & Soto, P. (Postdoctoral Researcher)
Agencia Nacional de Investigación y Desarrollo
15/04/23 → 14/04/26
Project: RESEARCH
-
FONDEF IDeA I+D - CIENCIA APLICADA - S/I: DESARROLLO DE UNA PRUEBA DIAGNÓSTICA DE ISQUEMIA CARDIACA EN SANGRE PERIFÉRICA BASADO EN LA CUANTIFICACIÓN DE VESÍCULAS EXTRACELULARES PROVENIENTES DEL CORAZÓN
Irarrazabal Muñoz, C. E. (Principal Investigator)
Agencia Nacional de Investigación y Desarrollo
3/01/22 → 30/12/22
Project: INNOVACIÓN Y DESARROLLO
-
CREA Y VALIDA I+D COLABORATIVO CORFO - S/I: DESARROLLO DE BIOMARCADORES PRESENTES EN VESÍCULAS EXTRACELULARES DE ENFERMEDAD CARDÍACA
Irarrazabal Muñoz, C. E. (Principal Investigator)
16/11/21 → 16/11/23
Project: INNOVACIÓN Y DESARROLLO
-
Método no invasivo de detección de daño renal midiendo marcadores de estrés oxidativo en microvesículas en la orina
Irarrazabal Muñoz, C. E. (Principal Investigator)
9/01/17 → 8/04/17
Project: RESEARCH
-
The protective role of Nuclear Factor of Activated T-cells 5 (NFAT5) during renal isquemia-reperfusion is dependent of inducible nitric oxide synthase (iNOS): participation of AQP-1
Irarrazabal Muñoz, C. E. (Principal Investigator)
15/03/15 → 15/03/18
Project: RESEARCH
-
Method For Monitoring, Diagnosis And/Or Prognosis Of Hypoxia Related Disorders Using NFAT5
Ernesto Irarrázabal Muñoz, C. (Inventor), 31 Mar 2026, IPC No. G01N31/00; G01N33/68; G01N33/53; C12Q1/68, Patent No. US14/349581, Priority date 1 Jan 2011, Priority No. US61/542446Research output: Patent
-
Metodología Para El Diagnóstico In Vitro De Enfermedad Cardiovascular
Ernesto Irarrázabal Muñoz, C. (Inventor), 31 Mar 2026, IPC No. G01N33/50; G01N33/68, Patent No. PCT/CL2024/050121, Priority date 1 Jan 2023, Priority No. CL202302964Research output: Patent
-
Metodología Para El Diagnóstico In Vitro De Enfermedad Cardiovascular
Ernesto Irarrázabal Muñoz, C. (Inventor), 31 Mar 2026, Patent No. CL202302964, Priority date 1 Jan 2023, Priority No. CL202302964Research output: Patent
-
Association of OPRM1 and OPRD1 Polymorphisms with Pain and Opioid Adverse Reactions in Colorectal Cancer
Gutiérrez-Cáceres, C., Ávila, N., Cerpa, L. C., Martínez, M. F., Irarrazabal, C. E., Torres, B., Barajas, O., Varela, N. M. & Quiñones, L. A., Feb 2025, In: Pharmaceuticals. 18, 2, 220.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Levels of Small Extracellular Vesicles Containing hERG-1 and Hsp47 as Potential Biomarkers for Cardiovascular Diseases
Osorio, L. A., Lozano, M., Soto, P., Moreno-Hidalgo, V., Arévalo-Gil, A., Ramírez-Balaguera, A., Hevia, D., Cifuentes, J., Hidalgo, Y., Alcayaga-Miranda, F., Pasten, C., Morales, D., Varela, D., Urquidi, C., Iturriaga, A., Rivera-Palma, A., Larrea-Gómez, R. & Irarrázabal, C. E., May 2024, In: International Journal of Molecular Sciences. 25, 9, 4913.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations
Courses
-
DOCB1210 Avances Biotecnológicos en Medicina
J. Monteiro, L., Contardo, I., Nardocci, G., Acevedo, J. P., Khoury, M., Figueroa, F., Luz Crawford, P. A., Pino-Lagos, K., Wyneken, Ú., Alcayaga-Miranda, F., Enrione, J., Irarrazabal Muñoz, C. E., Illanes, S., Batiz, L. F., Chaparro, A., Haidar, Z. S., Díaz Calderón, P. & Sadarangani Khainey, A. P. 2/08/21 → …
Course
-
NRC4144 Investigación Biomédica en la UANDES
Pino-Lagos, K., Contardo, I., Díaz Calderón, P., Luz Crawford, P. A., Wyneken, Ú., Illanes, S., Busso, D., J. Monteiro, L., Irarrazabal Muñoz, C. E. & Nardocci, G. 1/06/18 → …
Course